首页> 外国专利> LSC AND HSC SIGNATURES FOR PREDICTING SURVIVAL OF PATIENTS HAVING HEMATOLOGICAL CANCER

LSC AND HSC SIGNATURES FOR PREDICTING SURVIVAL OF PATIENTS HAVING HEMATOLOGICAL CANCER

机译:LSC和HSC签名可预测患有血液癌的患者的生存率

摘要

A method for determining prognosis in a subject having a hematological cancer comprising: a) determining an expression profile by measuring the gene expression levels of a set of genes selected from a leukemic stem cell (LSC) gene signature marker set or an hematopoietic stem cell (HSC) gene signature marker set, in a sample from a subject; and b) classifying the subject as having a good prognosis or a poor prognosis based on the expression profile; wherein a good prognosis predicts an increased likelihood of survival within a predetermined period after initial diagnosis and poor prognosis predicts a decreased likelihood of survival within the predetermined period after initial diagnosis.
机译:一种确定患有血液系统癌症的患者预后的方法,包括:a)通过测量选自白血病干细胞(LSC)基因签名标记集或造血干细胞的一组基因的基因表达水平来确定表达谱。 HSC)基因签名标记集,来自受试者的样品; b)基于表达谱将受试者分类为预后良好或不良;其中良好的预后预测在初始诊断后的预定时间内存活的可能性增加,而不良的预后则预测在初始诊断后的预定时间内存活的可能性降低。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号